Avacta Group plc has announced the appointment of David Bryant and Richard Hughes as Non-Executive Directors, effective immediately. David Bryant brings over 35 years of experience in the pharmaceutical industry, with previous roles at GSK, Pfizer, and Clinigen Group. Richard Hughes has over 30 years of experience in UK capital markets, having been involved in corporate finance, IPOs, and M&A. The appointments are expected to enhance the Board's capabilities as the company focuses on advancing its preCISION® platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.